4.7 Review

Targeting p73 in cancer

Journal

CANCER LETTERS
Volume 332, Issue 2, Pages 229-236

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.07.030

Keywords

Tumor suppressor genes; p73; p53; Molecular therapy

Categories

Funding

  1. European Research Council (P73CANCER)
  2. Deutsche Forschungsgemeinschaft [KFO210 STI182/3-1, TR81, A10]
  3. Deutsche Krebshilfe [107904]
  4. Deutsche Jose Carreras Leukamie-Stiftung [R 09/09]
  5. von Behring-Rontgen-Stiftung [51-0077]
  6. Kind-Philipp-Stiftung fur Leukamieforschung
  7. LOEWE (UGMLC, Tumor Inflammation)

Ask authors/readers for more resources

p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. In line with this, genetic studies in mice have confirmed that TAp73 acts as a tumor suppressor. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available